HZT-501, a novel combination of Ibuprofen (Ibu) and famotidine (Fam), provides pharmacokinetics comparable to that of commercially available Ibu and Fam in a patient-friendly dosing form: evaluation in healthy and renally-impaired subjects

Trial Profile

HZT-501, a novel combination of Ibuprofen (Ibu) and famotidine (Fam), provides pharmacokinetics comparable to that of commercially available Ibu and Fam in a patient-friendly dosing form: evaluation in healthy and renally-impaired subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2009

At a glance

  • Drugs Famotidine; Ibuprofen; Ibuprofen/famotidine
  • Indications Arthritis; Musculoskeletal pain; NSAID-induced gastrointestinal damage
  • Focus Pharmacokinetics
  • Sponsors Horizon Pharma USA
  • Most Recent Events

    • 26 Sep 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top